SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
NCT03867487
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Non-Alcoholic Fatty Liver Disease
NAFLD
Pediatric NAFLD
Interventions
DRUG:
Empagliflozin 10 MG
DRUG:
Placebo Oral Tablet
Sponsor
Justin Ryder